Company intelligence / Profile preview
Metaclipse Therapeutics
Atlanta, Georgia, United Statesmetaclipse.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Received FDA clearance for two INDs for Membrex™ personalized immunotherapy in head and neck cancer and triple negative breast cancer. Phase 1 clinical trials expected to begin enrolling patients in 2025.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Personalized immunotherapyVirus-like particles (VLPs)Membrane-bound biological adjuvants
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Syntekabio
Beyond the preview
Go deeper on Metaclipse Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metaclipse Therapeutics.